IDEAS home Printed from https://ideas.repec.org/a/bjc/journl/v8y2021i2p191-198.html
   My bibliography  Save this article

Applications of nanotechnology in vaccine development for coronavirus (SARS-CoV-2) disease (Covid-19)

Author

Listed:
  • Ravindra B. Malabadi

    (Department of Applied Botany, Mangalore University, Mangalagangotri-574199, Mangalore, Karnataka State, India)

  • Neelambika T. Meti

    (Plant Biotechnology Laboratory, Rajiv Gandhi Institute of IT and Biotechnology, Bharati Vidyapeeth University, Pune-Satara Road, Katraj, Pune – 411046, Maharashtra State, India)

  • Raju K. Chalannavar

    (Department of Applied Botany, Mangalore University, Mangalagangotri-574199, Mangalore, Karnataka State, India)

Abstract

This review paper highlights the use of nanotechnology as a new opportunities for the development of novel strategies in terms of prevention, detection, diagnosis and treatment of severe acute respiratory syndrome coronavirus (SARS-CoV-2). Coronavirus (SARS-CoV-2) disease (covid-19) infection is characterized by severe respiratory diseases, including bronchiolitis, pneumonia, high fever, throat infections, and common cold. SARS-CoV-2 infection is not limited to any particular class, and people of all age groups are vulnerable. The coronavirus is airborne mainly transmitted through droplets from the infected person or symptomatic patients or from asymptomatic people. The transmission of SARS-CoV-2 from one human to another human is much faster, which has already resulted in its spread around the world and led the WHO to declare the covid-19 outbreak as a global pandemic. These outbreaks have tested the limits of healthcare systems and have posed serious questions about anagement using conventional therapies and diagnostic tools. Therefore, new controlling measures to overcome this covid-19 pandemic is the development of a suitable and cost effective vaccines and therapeutics. Hence nanotechnology platforms in the development of vaccines and therapeutic drugs have been developed based on nanomedicine, and have the potential to become innovative alternatives for overcoming COVID-19. A nano-based (mRNA-lipid nanoparticle) formulation for SARS-CoV-2 vaccine and therapeutics is being developed as a delivery vehicle and found successful.

Suggested Citation

  • Ravindra B. Malabadi & Neelambika T. Meti & Raju K. Chalannavar, 2021. "Applications of nanotechnology in vaccine development for coronavirus (SARS-CoV-2) disease (Covid-19)," International Journal of Research and Scientific Innovation, International Journal of Research and Scientific Innovation (IJRSI), vol. 8(2), pages 191-198, February.
    • Handle: RePEc:bjc:journl:v:8:y:2021:i:2:p:191-198
    as

    Download full text from publisher

    File URL: https://www.rsisinternational.org/journals/ijrsi/digital-library/volume-8-issue-2/191-198.pdf
    Download Restriction: no
    File URL: https://www.rsisinternational.org/virtual-library/papers/applications-of-nanotechnology-in-vaccine-development-for-coronavirus-sars-cov-2-disease-covid-19/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Jing-Hui Tian & Nita Patel & Robert Haupt & Haixia Zhou & Stuart Weston & Holly Hammond & James Logue & Alyse D. Portnoff & James Norton & Mimi Guebre-Xabier & Bin Zhou & Kelsey Jacobson & Sonia Macie, 2021. "SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice," Nature Communications, Nature, vol. 12(1), pages 1-14, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Ravindra B. Malabadi & Neelambika T. Meti & Raju K. Chalannavar, 2021. "Role of herbal medicine for controlling coronavirus (SARS-CoV-2) disease (COVID-19)," International Journal of Research and Scientific Innovation, International Journal of Research and Scientific Innovation (IJRSI), vol. 8(2), pages 135-165, February.
    2. Rafael R. G. Machado & Jordyn L. Walker & Dionna Scharton & Grace H. Rafael & Brooke M. Mitchell & Rachel A. Reyna & William M. Souza & Jianying Liu & David H. Walker & Jessica A. Plante & Kenneth S. , 2023. "Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    3. Jimin Lee & Cameron Stewart & Alexandra Schäfer & Elizabeth M. Leaf & Young-Jun Park & Daniel Asarnow & John M. Powers & Catherine Treichel & Kaitlin R. Sprouse & Davide Corti & Ralph Baric & Neil P. , 2024. "A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines," Nature Communications, Nature, vol. 15(1), pages 1-13, December.
    4. Eike-Christian Wamhoff & Larance Ronsard & Jared Feldman & Grant A. Knappe & Blake M. Hauser & Anna Romanov & James Brett Case & Shilpa Sanapala & Evan C. Lam & Kerri J. St. Denis & Julie Boucau & Amy, 2024. "Enhancing antibody responses by multivalent antigen display on thymus-independent DNA origami scaffolds," Nature Communications, Nature, vol. 15(1), pages 1-13, December.
    5. Cai He & Jingyun Yang & Weiqi Hong & Zimin Chen & Dandan Peng & Hong Lei & Aqu Alu & Xuemei He & Zhenfei Bi & Xiaohua Jiang & Guowen Jia & Yun Yang & Yanan Zhou & Wenhai Yu & Cong Tang & Qing Huang & , 2022. "A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    6. James Logue & Robert M. Johnson & Nita Patel & Bin Zhou & Sonia Maciejewski & Bryant Foreman & Haixia Zhou & Alyse D. Portnoff & Jing-Hui Tian & Asma Rehman & Marisa E. McGrath & Robert E. Haupt & Stu, 2023. "Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    7. Eakachai Prompetchara & Chutitorn Ketloy & Mohamad-Gabriel Alameh & Kittipan Tharakhet & Papatsara Kaewpang & Nongnaphat Yostrerat & Patrawadee Pitakpolrat & Supranee Buranapraditkun & Suwimon Manopwi, 2023. "Immunogenicity and protective efficacy of SARS-CoV-2 mRNA vaccine encoding secreted non-stabilized spike in female mice," Nature Communications, Nature, vol. 14(1), pages 1-15, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bjc:journl:v:8:y:2021:i:2:p:191-198. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Dr. Renu Malsaria (email available below). General contact details of provider: https://rsisinternational.org/journals/ijrsi/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.